Ananth Jambur, Venkatesh Ravi, Burgoyne Karl, Gadasalli Rangaesh, Binford Robert, Gunatilake Sarath
University of California, Los Angeles and Harbor-UCLA Medical Center, Torrance, California 90509, USA.
Ann Clin Psychiatry. 2004 Apr-Jun;16(2):75-85. doi: 10.1080/10401230490453293.
There is compelling evidence that patients with schizophrenia are prone to gain weight. In addition, atypical antipsychotic (AAP) drugs also induce weight gain. All antipsychotic drugs produce weight gain but the potential varies. Many studies overwhelmingly confirm that AAP drugs produce substantially more weight gain in comparison to conventional antipsychotic drugs. Clozapine and olanzapine have the most weight inducing potential. Even ziprasidone, which is considered to be weight neutral, and aripiprazole a dopamine modulator produce weight gain in some. The pathophysiology of weight gain is complicated. Many neurohormones, neuropeptides, gut hormones, as well as adipose tissue and hair root derived hormones interact with environmental factors to produce weight gain. Management of weight gain is a difficult problem. Basic to treatment is an understanding of the etiology. Drug induced obesity provides a unique opportunity to psychiatrists to understand this clinically important problem. In the absence of this knowledge, prevention is the best hope. Education, diet control and simple behavioral measures may prevent excessive weight gain. In those with weight gain, treatment can be attempted with pharmacotherapy with careful monitoring of the side effects.
有确凿证据表明,精神分裂症患者容易体重增加。此外,非典型抗精神病药物(AAP)也会导致体重增加。所有抗精神病药物都会引起体重增加,但可能性各不相同。许多研究压倒性地证实,与传统抗精神病药物相比,AAP药物导致的体重增加要多得多。氯氮平和奥氮平具有最强的致体重增加潜力。即使是被认为对体重无影响的齐拉西酮以及多巴胺调节剂阿立哌唑,在某些患者中也会导致体重增加。体重增加的病理生理学很复杂。许多神经激素、神经肽、肠道激素以及脂肪组织和发根衍生的激素与环境因素相互作用,从而导致体重增加。体重增加的管理是个难题。治疗的基础是了解病因。药物性肥胖为精神科医生理解这个临床上重要的问题提供了独特的机会。在缺乏这方面知识的情况下,预防是最大的希望。教育、饮食控制和简单的行为措施可能会防止体重过度增加。对于体重增加的患者,可以尝试药物治疗,但要仔细监测副作用。